Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Benjamin L, MD
13 Machi 2021 21:01:07
Clarithromycin na ujauzito
Clarithromycin ni dawa inayofanana umbo na dawa zingine kundi la macrolide ambalo linahisisha dawa kama vile azithromycin, dirithromycin, erythromycin, na troleandomycin.
Tafiti za uzazi wa wanyama zinaonyesha zina hatari kubwa kudhuru uumbaji wa kichanga, hata hivyo taarifa za matumizi kwenye ujauzito zinatoa mapendekezo kwamba, hata kama hatari ipo kwa binadamu, hatarihiyo ni kidogo sana.
Ushauri dhidi ya matumizi kwa mama mjamzito
Inapatana na Ujauzito
'Inapatana na ujauzito' ina maana gani?
Uzoefu wa matumizi kwa binadamu kuhusu dawa hii au dawa zingine zilizo kundi moja au zenye kufanya kazi kwa utaratibu unaofanana, zinatosha kuonyesha kuwa, madhara kwa kichanga tumboni ni madogo sana au hakuna kabisa. Tafiti za uzazi kwa wanyama hazina uhalisia kwa binadamu
Ushauri wa matumizi kwa mama anayenyonyesha
Inapatana na kunyonyesha
'Inapatana na kunyonyesha' ina maana gani?
Kiasi kidogo cha dawa hii kinawezekana kuingia kwenye maziwa ya mama, kiasi hiki hakina mashiko ya kusababisha sumu kwa kichanga anayenyonya. Dawa hii haitarajiwi kusababisha madhara kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023 17:21:36
Rejea za mada hii
1. Andersen JT, et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a registerbased nationwide cohort study. PLoS One 2013;8:e53327. doi:10.1371/journal.pone.0053327. Epub 2013 Jan 2.
2. Bar-Oz B, et al. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observations study. Drug Saf 2012;35:589–98.
3. Bar-Oz B, et al.Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study. Eur J Obstet Gynecol Reprod Biol 2008;141:31–4.
4. Einarson A, et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998;15:523–5.
5. Escobar LF, et al. Charge association. In: Buyse ML, ed. Birth Defects Encyclopedia. Vol. 1. Dover, MA: Center for Birth Defects Information Services, 1990:308–9.
6. Goldstein LH, et al. The safety of macrolides during lactation. Breastfeed Med 2009;4:157–200.
7. Jacoby EB, et al. Helicobacter pylori infection and persistent hyperemesis gravidarum. Am J Perinatol 1999;16:85–8.
8. Schick B, et al. Pregnancy outcome following exposure to clarithromycin (abstract). Abstracts of the Ninth International Conference of the Organization of Teratology Information Services, May 2–4, 1996, Salt Lake City, Utah. Reprod Toxicol 1996;10:162.
9. Sedimayr TH, et al. Clarithromycin, a new macrolide antibiotic: effectiveness in puerperal infections and pharmacokinetics in breast milk. Geburtshilfe Frauenheilkd 1993;53:488–91.
10. Sorensen HT, et al. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis 2003;35:104–6.
11. Tellem R, et al. Pregnancy outcome after gestational exposure to the new macrolides: a prospective controlled cohort study (abstract). Reprod Toxicol 2005;20:484.
12. Witt A, et al. Placental transfer of clarithromycin surpasses other macrolide antibiotics. Am J Obstet Gynecol 2003;188:816–9.